Variation in the gene coding for the M5 Muscarinic receptor (CHRM5) influences cigarette dose but is not associated with dependence to drugs of addiction: evidence from a prospective population based cohort study of young adults

BackgroundThe mesolimbic structures of the brain are important in the anticipation and perception of reward. Moreover, many drugs of addiction elicit their response in these structures. The M5 muscarinic receptor (M5R) is expressed in dopamine-containing neurones of the substantia nigra pars compacta and ventral tegmental area, and regulates the release of mesolimbic dopamine. Mice lacking M5R show a substantial reduction in both reward and withdrawal responses to morphine and cocaine. The CHRM5, the gene that codes for the M5R, is a strong biological candidate for a role in human addiction. We screened the coding and core promoter sequences of CHRM5 using denaturing high performance liquid chromatography to identify common polymorphisms. Additional polymorphisms within the coding and core promoter regions that were identified through dbSNP were validated in the test population. We investigated whether these polymorphisms influence substance dependence and dose in a cohort of 1947 young Australians.ResultsAnalysis was performed on 815 participants of European ancestry who were interviewed at wave 8 of the cohort study and provided DNA. We observed a 26.8% increase in cigarette consumption in carriers of the rs7162140 T-allele, equating to 20.1 cigarettes per week (p=0.01). Carriers of the rs7162140 T-allele were also found to have nearly a 3-fold increased risk of developing cannabis dependence (OR=2.9 (95%CI 1.1-7.4); p=0.03).ConclusionOur data suggest that variation within the CHRM5 locus may play an important role in tobacco and cannabis but not alcohol addiction in European ancestry populations. This is the first study to show an association between CHRM5 and substance use in humans. These data support the further investigation of this gene as a risk factor in substance use and dependence.

[1]  D. Flynn,et al.  The M5 (m5) receptor subtype: fact or fiction? , 1997, Life sciences.

[2]  R. Anney,et al.  Association Between Dependent Smoking and a Polymorphism in the Tyrosine Hydroxylase Gene in a Prospective Population-Based Study of Adolescent Health , 2004, Behavior genetics.

[3]  J. Wess,et al.  Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  W. Alexander.  American psychiatric association. , 2008, P & T : a peer-reviewed journal for formulary management.

[5]  J. Wess,et al.  Role for M5 muscarinic acetylcholine receptors in cocaine addiction , 2003, Journal of neuroscience research.

[6]  L. Degenhardt,et al.  The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. , 1999, Addiction.

[7]  Michael C O'Donovan,et al.  Strong bias in the location of functional promoter polymorphisms , 2005, Human mutation.

[8]  L. Kozlowski,et al.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.

[9]  M. Parmentier,et al.  Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. , 1999, Science.

[10]  L. Heston,et al.  Delineation of genetic predisposition to multifactorial disease: a general approach on the threshold of feasibility. , 1992, Genomics.

[11]  J. Yeomans,et al.  M5 Muscarinic Receptors Are Required for Prolonged Accumbal Dopamine Release after Electrical Stimulation of the Pons in Mice , 2002, The Journal of Neuroscience.

[12]  C. Blaha,et al.  Midbrain muscarinic receptor mechanisms underlying regulation of mesoaccumbens and nigrostriatal dopaminergic transmission in the rat , 2005, The European journal of neuroscience.

[13]  T. Wenger,et al.  Neuromorphological background of cannabis addiction , 2003, Brain Research Bulletin.

[14]  Alessio Squassina,et al.  Linkage of M5 Muscarinic and α7-Nicotinic Receptor Genes on 15q13 to Schizophrenia , 2004, Neuropsychobiology.

[15]  F. Leslie,et al.  Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons , 2002, The Journal of comparative neurology.

[16]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .

[17]  A. Levey,et al.  Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Yeomans,et al.  M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation. , 2001, Life sciences.

[19]  Jonathan A C Sterne,et al.  Sifting the evidence—what's wrong with significance tests? , 2001, BMJ : British Medical Journal.

[20]  J. Palacios,et al.  Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry , 1990, Neuroscience Letters.